

Title (en)

MEDICAMENT FOR THE STIMULATION OF LEUCOPOIESIS AND TREATMENT OF TUMOUR AND PROTOZOAN DISEASES ACARINOSIS AND ARTHROPOD-BORNE DISEASES AND A METHOD FOR PRODUCTION THEREOF

Title (de)

ARZNEIMITTEL ZUR STIMULIERUNG DER LEUKOPOESE, ZUR BEHANDLUNG VON TUMOR- UND PROTOZOENERKRANKUNGEN, VON AKARINOSIS, ARTHROPODIASIS UND VERFAHREN ZU SEINER HERSTELLUNG

Title (fr)

MEDICAMENT POUR STIMULER LA LEUCOPOESE, POUR TRAITER DES AFFECTIONS TUMORALES ET DES PROTOZOOSES, L'ACARINOSE, L'ARTHROPODIASE ET PROCESSES PERMETTANT DE LE PRODUIRE

Publication

**EP 1267943 A2 20030102 (DE)**

Application

**EP 01938070 A 20010329**

Priority

- DE 10015814 A 20000330
- EP 0103609 W 20010329

Abstract (en)

[origin: WO0172289A2] The invention relates to pharmaceutical formulations for the stimulation of leucopoiesis and treatment of tumour and protozoan diseases, acarinosis and diseases caused by arthropods, characterised in that they contain an effective mixture of a) at least one phospholipid compound of formula (I), where R<1> = a 16 to 24 C hydrocarbon residue, R<2>, R<3> and R<4> = independently, H, C1-C5 alkyl, C3-C6 cycloalkyl or C1-C5 hydroxyalkyl, where two of R<2>, R<3> and R<4> together form a C2-C5 alkylene group, optionally substituted with an -O-, -S- or NR<5> group, where R<5> = H, C1-C5 alkyl, C3-C6 cycloalkyl or C1-C5 hydroxyalkyl and n = a whole number from 2 to 6 as an active ingredient at from 30 to 60 mol %, b) cholesterol, and/or cholesterol derivatives at from 25 to 65 mol %, c) a phosphatidylmono- or phosphatidyloligo-glycerine, containing at least one oleyl group at from 5 to 15 mol %, where a), b) and c) together make 100 mol % and d) a water-miscible physiologically acceptable alcohol with 2 to 4 C atoms, which optionally contains water and optionally conventional pharmaceutical adjuncts, whereby the above components are in the form of a complex dispersed in water. The invention further relates to a method for the production thereof.

IPC 1-7

**A61K 47/48**

IPC 8 full level

**A61K 9/10** (2006.01); **A61K 9/00** (2006.01); **A61K 9/127** (2006.01); **A61K 31/56** (2006.01); **A61K 31/575** (2006.01); **A61K 31/685** (2006.01); **A61K 31/7048** (2006.01); **A61K 47/10** (2006.01); **A61K 47/24** (2006.01); **A61K 47/28** (2006.01); **A61P 7/00** (2006.01); **A61P 33/02** (2006.01); **A61P 33/14** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP US)

**A61K 9/0095** (2013.01 - EP US); **A61K 9/127** (2013.01 - EP US); **A61K 31/56** (2013.01 - EP US); **A61K 31/575** (2013.01 - EP US); **A61K 31/685** (2013.01 - EP US); **A61P 7/00** (2017.12 - EP); **A61P 33/02** (2017.12 - EP); **A61P 33/14** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **Y02A 50/30** (2017.12 - EP US)

Citation (search report)

See references of WO 0172289A2

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

**WO 0172289 A2 20011004; WO 0172289 A3 20020418;** AU 6382801 A 20011008; BR 0109799 A 20030121; CA 2404322 A1 20020924; CN 1426311 A 20030625; DE 10015814 A1 20011011; EP 1267943 A2 20030102; IL 151926 A0 20030410; JP 2003528134 A 20030924; MX PA02009434 A 20030922; US 2003199476 A1 20031023

DOCDB simple family (application)

**EP 0103609 W 20010329;** AU 6382801 A 20010329; BR 0109799 A 20010329; CA 2404322 A 20010329; CN 01808631 A 20010329; DE 10015814 A 20000330; EP 01938070 A 20010329; IL 15192601 A 20010329; JP 2001570250 A 20010329; MX PA02009434 A 20010329; US 24019903 A 20030523